14 completed, 8 terminated, 6 recruiting, 5 active not recruiting. 22 Phase 2, 13 Phase 1, 3 Phase 3, 1 Phase 4.
Follow Advanced Accelerator Applications: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer Biopsy, Biospecimen Collection, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 10 | 2026-06-30 | 2026-06-05 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer 177Lu-PSMA-617 - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 48 | 2026-04-07 | 2026-06-04 |
| Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer [177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University Hospital, Essen | 1 | 2025-08-25 | 2026-03-13 |
| Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in 77 Lu-DOTA0-Tyr3-Octreotate - Metastatic Nasopharyngeal Cancer | Phase 2 | Suspended | National Cancer Centre, Singapore | 25 | 2023-05-05 | 2026-05-22 |
| Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) Liquid Biopsy, Archival Tumor DNA sequencing - Metastatic Prostate Cancer | Recruiting | SOLTI Breast Cancer Research Group | 240 | 2023-03-28 | 2025-08-06 | |
| Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors Cabozantinib, Lu-177 - Neuroendocrine Tumors | Phase 1 | Active not recruiting | Providence Health & Services | 6 | 2022-12-28 | 2026-04-13 |
| Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs Lutetium [177Lu] oxodotreotide/dotatate - Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma | Phase 2 | Active not recruiting | Advanced Accelerator Applications | 11 | 2022-08-31 | 2026-02-12 |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC 177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 2 | Unknown | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 93 | 2022-04-29 | 2023-12-15 |
| Lutathera and ASTX727 in Neuroendocrine Tumours ASTX727, Lutathera - Neuroendocrine Tumors | Phase 1 | Recruiting | Imperial College London | 37 | 2022-04-25 | 2026-11-12 |
| EBRT + Lu-PSMA for N1M0 Prostate Cancer 177Lu-PSMA-617, EBRT - Prostatic Neoplasm | Phase 1 | Completed | The Netherlands Cancer Institute | 14 | 2021-12-20 | 2025-12-10 |
| Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection, Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection, LUTATHERA® by intra-arterial hepatic (IAH) injection - Neuroendocrine Tumor, Liver Metastases | Phase 2 | Recruiting | University Hospital, Bordeaux | 23 | 2021-09-24 | 2025-07-23 |
| 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma 177Lu-DOTATATE - Neuroblastoma Recurrent, Neuroblastoma | Phase 2 | Recruiting | Jakob Stenman | 24 | 2021-05-19 | 2026-11-09 |
| Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors | Phase 4 | Completed | Advanced Accelerator Applications | 42 | 2021-01-25 | 2025-01-24 |
| Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Lutathera - Carcinoid Heart Disease, Carcinoid Syndrome | Phase 2 | Unknown | King's College Hospital NHS Trust | 20 | 2020-10-01 | 2020-08-04 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma | Phase 1 / Phase 2 | Withdrawn | Sue O'Dorisio | 2020-08-04 | 2021-06-08 | |
| Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer 177Lu-PSMA-617 - Prostate Cancer | Phase 2 | Completed | Radboud University Medical Center | 58 | 2020-07-20 | 2026-02-27 |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours 177Lu-DOTA-TATE + olaparib - Clinical Trial, Phase I, Neuroendocrine Tumors | Phase 1 | Completed | Vastra Gotaland Region | 18 | 2020-04-23 | 2026-04-14 |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy 177Lu-PSMA-617, Docetaxel - Metastatic Hormone Naive Prostate Cancer | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 130 | 2020-04-21 | 2025-07-11 |
| Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 3 | Active not recruiting | Advanced Accelerator Applications | 226 | 2020-01-08 | 2026-01-21 |
| Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract 68Ga-DOTATATE, Positron Emission Tomography (PET) Scan - Neuroendocrine Carcinoma | Completed | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2019-09-25 | 2026-03-31 |
Showing 20 of 39. Sign in to see all of them.
Neuroendocrine Tumors (9) · Prostatic Neoplasms (8) · Neoplasms (5) · Breast Neoplasms (3) · Gastro-enteropancreatic neuroendocrine tumor (3) · Genital Neoplasms, Male (3) · Neoplasms by Site (3) · Prostatic Diseases (3) · Urogenital Neoplasms (3) · Carcinoid Tumor (2) · Paraganglioma (2) · Pheochromocytoma (2) · Small Cell Lung Carcinoma (2) · Spondylitis, Ankylosing (2) · Arthritis, Psoriatic (1)
lutetium Lu 177 dotatate (13) · Pluvicto (6) · Ipilimumab (2) · Lutetium-177 (2) · Nivolumab (2) · Octreotide (2) · gallium Ga 68 dotatate (2) · Biopsy (1) · Docetaxel (1) · Ga(III)-DOTATOC (1) · Injections (1) · Liquid Biopsy (1) · Lutetium (1) · Magnetic Resonance Spectroscopy (1) · PSMA-11 (1)
United States (15) · France (10) · United Kingdom (9) · Spain (8) · Netherlands (6) · Canada (4) · Germany (3) · Italy (3) · Australia (2) · Austria (2) · Poland (2) · Portugal (2) · Sweden (2) · Switzerland (2) · Belgium (1)
Arun Azad, MBBS PhD FRACP (1) · Chul Kim, MD (1) · Daniel Tan, BSc, MBBS, PhD (1) · Dominique Le Guludec, MD, PhD (1) · Emmanuel Seront, MD (1) · Hagen Kennecke, MD (1) · Jakob Stenman, MD PhD (1) · James Nagarajah, Prof. (1) · John O Prior, PhD MD (1) · John Prior, MD, PhD (1) · Jonathan Strosberg, MD (1)
PMID 28076709, PMID 29878866, PMID 32123969, PMID 32616557, PMID 32928177, PMID 33189510, PMID 33973550, PMID 34736509, PMID 34793718, PMID 34829796, PMID 35359899, PMID 36959540, PMID 37879695, PMID 38753757, PMID 38851203, PMID 39293461, PMID 39570708, PMID 39915126, PMID 40198358, PMID 40473457, PMID 41073165, PMID 41926960, PMID 42225102, PMID 42604001
2023 (3), 2017 (2), 2019 (2), 2009 (1)